CAJ | 학술논문

目的：研究BRG1在人脑胶质瘤中的表达情况，并探讨其表达水平与胶质瘤的恶性程度及发生、发展的关系。方法：采用组织芯片及免疫组化技术，评估BRG1在120例良性胶质瘤组织（I~II级）、70例恶性胶质瘤组织（III–IV级）、8例正常脑组织和8例癌旁组织中的染色情况。结果：免疫组化结果显示：BRG1在正常脑组织中阳性表达率为25%（2/8），在癌旁组织中阳性表达率为25%（2/8），在良性胶质瘤组织中阳性表达率为80.8%（97/120），在恶性胶质瘤组织中为82.9%（58/70）。在癌旁组织与良性胶质瘤之间、癌旁组织与恶性胶质瘤之间差异均有统计学意义（P=0.000），但是在良性和恶性之间差异无统计学意义（P=0.847）。BRG1的表达与临床病理参数之间也没有相关性。结论：BRG1在人脑胶质瘤中的表达明显高于正常脑组织和癌旁组织，并与胶质瘤的发生具有一定的相关性。BRG1在胶质瘤的发生过程中可能有重要作用。
목적：연구BRG1재인뇌효질류중적표체정황，병탐토기표체수평여효질류적악성정도급발생、발전적관계。방법：채용조직심편급면역조화기술，평고BRG1재120례량성효질류조직（I~II급）、70례악성효질류조직（III–IV급）、8례정상뇌조직화8례암방조직중적염색정황。결과：면역조화결과현시：BRG1재정상뇌조직중양성표체솔위25%（2/8），재암방조직중양성표체솔위25%（2/8），재량성효질류조직중양성표체솔위80.8%（97/120），재악성효질류조직중위82.9%（58/70）。재암방조직여량성효질류지간、암방조직여악성효질류지간차이균유통계학의의（P=0.000），단시재량성화악성지간차이무통계학의의（P=0.847）。BRG1적표체여림상병리삼수지간야몰유상관성。결론：BRG1재인뇌효질류중적표체명현고우정상뇌조직화암방조직，병여효질류적발생구유일정적상관성。BRG1재효질류적발생과정중가능유중요작용。
Objective:To investigate the expression level of BRG1 in human glioma,and to explore the relationship BRG1 with malignant degree,tumorigenesis, and progression of human glioma.Method:BRG1 staining in 120 benign glioma tissues (Grades I to II), 70 malignant glioma tissues (Grades III to IV) ,8 normal brain tissues and 8 tumor adjacent normal brain tissues were tested by tissue microarray and immunohistochemistry.Result:BRG1 nuclear staining was observed in 25%(2/8) normal brain tissue,25%(2/8) tumor adjacent normal brain tissue, 80.8%(97/120) benign tumor and 82.9%(58/70) malignant tumor. The significant difference in BRG1 staining was observed between tumor adjacent normal brain tissue and benign tumor and between tumor adjacent normal brain tissue and malignant tumor (P=0.000). However, there was no significant difference in BRG1 staining between benign tumor and malignant tumor (P=0.847). It was showed that there was no significant correlation between BRG1 expression and clinicopathological parameters.Conclusion:BRG1 expression is significantly increased in human glioma than in normal brain tissues and tumor adjacent normal brain tissues. The BRG1 gene plays an important role in the progression of human glioma, knockdown of BRG1 may serve as a potential therapeutic target for human glioma.